Global Gastric Cancer

Global Gastric Cancer Market Research Report: Forecast (2022-2027)

By Diagnosis (Blood Tests, Upper Endoscopy, Laparoscopy, Imaging), By Treatment (Chemotherapy, Surgery, Targeted Drug Therapy, Others (Immunotherapy, etc.)), By End-User (Hospitals, Clinics, Specializ Read more

  • Healthcare
  • Jun 2022
  • 188
  • HC22092

Market Definition

Gastric cancer is the abnormal cell growth across the stomach's inner lining, which progresses slowly and shows early signs like indigestion, slight nausea, heartburn, loss of appetite, etc. Yet, the gradual tumor development escalates the severity of symptoms like stomach pain, yellowish eyes or skin, swelling in the stomach, vomiting, blood in stool, constipation, & weight loss, among others. Gastric Cancers are also commonly known as stomach cancers. There are various treatments for this illness, and each depends upon parameters like the stage, patient age, & overall health.

Market Insights

The Global Gastric Cancer Market is projected to grow at a CAGR of around 14.80% during the forecast period, i.e., 2022-27. The market is driven by the rapidly increasing number of people suffering from Gastric Cancer and rapid developments in the healthcare sector offering quicker diagnosis & effective treatments for the same.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 14.80%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, France, Russia, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, Rest of Asia Pacific
South America: Brazil, Argentina, Rest of South America
Middle East & Africa: Israel, GCC, South Africa, Rest of The Middle East & Africa
Key Companies Profiled

AstraZeneca PLC, Bristol Myers Squibb, Celltrion Inc., Jiangsu Hengrui Medicine Co., Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Others,

Unit Denominations USD Million/Billion

 

Besides, the mounting awareness among people about the availability of diagnosis & treatment of gastric cancer is portraying a swiftly escalating cancer screening tests across different countries worldwide and encouraging the leading biopharma companies to increase their production & distribution capacities to cater to the rising needs of patients for treatment. For instance:

  • In November 2019, Pfizer & EMD Serono, Inc. revealed positive results from their phase III clinical study on Avelumab for advanced gastric cancer treatment.
  • In March 2019, AstraZeneca incorporated with Daiichi Sankyo, Inc., for the development & commercialization of an antibody-drug conjugate, Trastuzumab Deruxtecan, under investigation for gastric carcinoma.

Moreover, various research & development activities to bring innovations in existing drugs & introduce new medications for gastric cancer are also augmenting the market growth. It, in turn, is leading to several mergers & acquisitions among prominent players for enhanced product portfolio & improved reachability.

Furthermore, massive support from the governments of different countries worldwide through investments & imposition of favorable policies for various clinical trials of therapies are also playing a prominent role in boosting the Global Gastric Cancer Market.

Global Gastric Cancer Market Research Report: Forecast (2022-2027)

Market Segmentation

Based on Treatment:

  • Chemotherapy
  • Surgery
  • Targeted Drug Therapy
  • Others (Immunotherapy, etc.)

Of all treatments, surgery is anticipated to contribute substantially to the growth of the Global Gastric Cancer Market during 2022-27. It owes principally to the rising inclination of gastric cancer patients toward surgical treatment due to its applicability to cancers of all stages. Besides, growing public awareness about the availability of different surgeries depending upon parameters like tumor growth, location, patient health, etc., are other crucial aspects stimulating the market growth for surgery.

On the other hand, Chemotherapy can be given to patients with gastric cancer in three formations:

  • Before surgery, i.e., neoadjuvant treatment, is sometimes given to patients alongside radiation therapy (chemoradiation). This treatment is prominently to shrink the size of the tumor and make it easy to remove through surgery while also even possibly avoiding cancer from coming back. 
  • After Surgery, adjuvant treatment, is done with the prime goal to kill small to see cancer that might be present in any area after the removal of the tumor in surgery and eliminating the possibilities of reoccurrence. In some cases, Chemotherapy is also given radiation therapy after the surgery is performed.
  • Chemotherapy as Primary Treatment is performed in case the tumor has metastasized to distant organs or cannot be removed due to any other reasons. In such cases, Chemotherapy may help in reducing cancer or slowing down the growth pace, offering longer life to the patient. 

The most prominent Chemotherapy drugs used for gastric cancer treatment include:

  • 5-FU (fluorouracil) given with leucovorin (folinic acid)
  • Carboplatin
  • Cisplatin
  • Epirubicin
  • Oxaliplatin
  • Capecitabine
  • Paclitaxel
  • Docetaxel
  • Irinotecan

A few of the aforementioned Chemotherapy drugs are also used in combination with targeted therapy in some cases of gastric cancer. In cases of early-stage gastric cancers, drug combinations used before and/or after surgery include:

  • Oxaliplatin in combination with 5-FU/leucovorin (FOLFOX), or capecitabine (CAPOX)
  • Cisplatin in combination with either 5-FU or capecitabine
  • Docetaxel or paclitaxel in combination with either 5-FU or capecitabine
  • FLOT (5-FU/leucovorin, oxaliplatin, &docetaxel)
  • Paclitaxel, in combination with carboplatin
  • In case the Chemotherapy is done with radiation therapy, single drugs like 5-FU or capecitabine may be used.

Based on End-Users:

  • Hospitals
  • Clinics
  • Specialized Cancer Centers
  • Others (Ambulatory Surgery Centers, etc.)

Here, hospitals are anticipated to dominate the market with the largest share during 2022-27. It owes principally to the growing focus of governments of different countries on developing the healthcare infrastructure and building several multi-specialty hospitals to meet the burgeoning patient needs and attract medical tourism to the country.

Besides, with the swift escalation in the number of hospitals, the demand for the procurement of various diagnosis equipment & treatment drugs is rising and demonstrating massive financial flow in the industry. It, in turn, is also generating growth opportunities for the leading players to increase their development & distribution capabilities to cater to patient requirements globally.

Moreover, as every hospital is equipped with various laboratories & pharmacies, the constant need to have equipment & drugs available at hospitals is also playing a prominent role in augmenting the overall growth of the Global Gastric Cancer Market through 2027.

Regional Landscape

Geographically, the Global Gastric Cancer Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Of all regions globally, Asia-Pacific is anticipated to dominate the Gastric Cancer Market with the largest share during 2022-27. It attributes primarily to the vast patient pool of stomach cancer across countries like China, Japan, South Korea, & India due to active screening programs by their respective governments. It, in turn, is generating growth opportunities for the leading players to bring advancements in disease treatments for greater effectiveness & success rates, which, in turn, is augmenting the growth of the Asia-Pacific Gastric Cancer Market.

Besides, massive government investments in various research & development activities for innovations in gastric cancer diagnosis & treatment entwined with favorable policies for clinical trials for drugs shall also boost the regional market growth over the forecast years. Due to such initiatives, the leading biopharma companies in the region are introducing new products & innovations in existing drugs and, in turn, contributing to the expansion of the gastric cancer market across Asia-Pacific.

Possible Restraint in the Global Gastric Cancer Market

  • High Treatment Costs & Insufficient Financial Support

Since certain diagnoses & therapies of most cancers, including gastric cancer, incur high costs, it limits the number of patients opting for treatments due to their inability to afford them. Besides, some people also find difficulties attaining financial support from various health insurance companies due to rigid policies. These aspects are acting as prominent growth restraints for the Global Gastric Cancer Market.

Key Questions Answered in the Market Research Report:

  1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Gastric Cancer Market?
  2. What are the region-wise industry size, growth drivers, and challenges?
  3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Gastric Cancer Market?
  4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Gastric Cancer Market based on the competitive benchmarking matrix?
  5. What are the key results derived from surveys conducted during the Global Gastric Cancer Market study?

Frequently Asked Questions

A. The Global Gastric Cancer Market is projected to grow at a CAGR of around 14.80% during 2022-27.

A. The active participation of the leading players in various research & development activities for advancements in gastric cancer diagnosis & treatment, coupled with massive government support through favorable policies for conducting clinical trials and rising healthcare expenditure, are the prominent factors driving the Global Gastric Cancer Market. On the other hand, the high cost of gastric cancer diagnosis & treatment would hamper the fledged growth of the market through 2027.

A. Surgery is anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Gastric Cancer Market over the forecast years.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Gastric Cancer Market Trends & Insights
  4. Global Gastric Cancer Market Regulation & Policy, By Country
  5. Global Gastric Cancer Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Gastric Cancer Market Hotspot and Opportunities
  7. Global Gastric Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Blood Tests
        2. Upper Endoscopy
        3. Laparoscopy
        4. Imaging
      2. By Treatment
        1. Chemotherapy
        2. Surgery
        3. Targeted Drug Therapy
        4. Others (Immunotherapy, etc.)
      3. By End-User
        1. Hospitals
        2. Clinics
        3. Specialized Cancer Centers
        4. Others (Ambulatory Surgery Centers, etc.)
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Gastric Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Gastric Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Gastric Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Gastric Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Gastric Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia Pacific
  13. Global Gastric Cancer Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AstraZeneca PLC
      2. Bristol Myers Squibb
      3. Celltrion Inc.
      4. Jiangsu Hengrui Medicine Co., Ltd.
      5. Eli Lilly and Company
      6. GlaxoSmithKline PLC
      7. F. Hoffmann-La Roche AG
      8. Merck & Co., Inc.
      9. Novartis International AG
      10. Pfizer Inc.
      11. Others
  15. Disclaimer
Gastric Cancer Market Segmentation